Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.
Edita NavratilovaJanice OyarzoTrent AndersonRon S BroideSudhakar R SubramaniamEdwin J Vazquez-CintronMitchell F BrinTodd J SchwedtDavid W DodickFrank PorrecaPublished in: Cephalalgia : an international journal of headache (2022)
Mild traumatic brain injury induced transient headache-like pain followed by long lasting sensitization and persistent vulnerability to a normally innocuous stress stimulus, respectively modeling acute and persistent post-traumatic headache.. Administration of onabotulinumtoxinA following the resolution of acute post-traumatic headache diminished persistent post-traumatic headache but the effects were transient, suggesting that underlying persistent mild traumatic brain injury-induced maladaptations were not reversed. In contrast, early onabotulinumtoxinA administration fully blocked both acute post-traumatic headache as well as the transition to persistent post-traumatic headache suggesting prevention of neural adaptations that promote vulnerability to headache-like pain. Additionally, the degree of acute post-traumatic headache was predictive of risk of persistent post-traumatic headache.
Keyphrases
- mild traumatic brain injury
- liver failure
- drug induced
- respiratory failure
- chronic pain
- aortic dissection
- climate change
- magnetic resonance imaging
- computed tomography
- stem cells
- neuropathic pain
- diabetic rats
- endothelial cells
- high intensity
- brain injury
- smoking cessation
- combination therapy
- single molecule
- postoperative pain